Embigin (EMB), a transmembrane glycoprotein of the immunoglobulin superfamily (35), is involved in the occurrence and development of prostate cancer, pancreatic cancer and breast cancer, and is associated with poor prognosis in cancer patients (36–38), but not in reports of gastric cancer. Here, EMB is linked to prostate carcinoma.